<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04982575</url>
  </required_header>
  <id_info>
    <org_study_id>NN9838-4862</org_study_id>
    <nct_id>NCT04982575</nct_id>
  </id_info>
  <brief_title>Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes</brief_title>
  <official_title>Efficacy and Safety of Co-administration of Cagrilintide s.c. 2.4 mg and Semaglutide s.c. 2.4 mg Once Weekly in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study looks at how well a new medicine called cagrilintide works together with&#xD;
      semaglutide on blood sugar levels in people with type 2 diabetes compared to cagrilintide&#xD;
      alone or semaglutide alone.&#xD;
&#xD;
      Before a new medicine can be prescribed to people it needs to be tested to see if it is safe&#xD;
      and effective.&#xD;
&#xD;
      Participants will either get cagrilintide and semaglutide together or cagrilintide and a&#xD;
      dummy medicine or semaglutide and a dummy medicine. Which treatment participants get is&#xD;
      decided by chance.&#xD;
&#xD;
      A dummy medicine (placebo) looks like the study medicine but does not contain any active&#xD;
      medicine. The dummy medicine is in the study to see if the study medicine works as expected.&#xD;
&#xD;
      Participants will get 2 injections per week on the same day. Participants will take the study&#xD;
      medicine with a pen. A pen is a medical tool with a needle used for injections under the&#xD;
      skin. The study doctor or staff will show how.&#xD;
&#xD;
      The study will last for about 39 weeks. Participants will have 12 visits at the clinic and 5&#xD;
      phone calls with the study doctor.&#xD;
&#xD;
      At 6 of the clinic visits participants must not eat and drink for 8 hours before the visit&#xD;
      (water is allowed).&#xD;
&#xD;
      Women who can become pregnant cannot take part in this study. Only women that are surgically&#xD;
      sterilised or post-menopausal are allowed to participate in this study Women cannot take part&#xD;
      if pregnant, breast-feeding or plan to get pregnant during the study period&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2, 2021</start_date>
  <completion_date type="Anticipated">July 4, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 23, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in glycated haemoglobin (HbA1c)</measure>
    <time_frame>From baseline (week 0) to week 32</time_frame>
    <description>percent-point</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose (FPG)</measure>
    <time_frame>From baseline (week 0) to week 32</time_frame>
    <description>mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose (FPG)</measure>
    <time_frame>From baseline (week 0) to week 32</time_frame>
    <description>mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM: Change in mean glucose</measure>
    <time_frame>From baseline (week 0) to week 32</time_frame>
    <description>mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM: Change in mean glucose</measure>
    <time_frame>From baseline (week 0) to week 32</time_frame>
    <description>mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM: Time above range (TAR) greater than 10.0 mmol/L (greater than 180 mg/dL)</measure>
    <time_frame>At week 32</time_frame>
    <description>percent of readings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM: Time in range (TIR) 3.9-10.0 mmol/L (70-180 mg/dL)</measure>
    <time_frame>At week 32</time_frame>
    <description>percent of readings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>From baseline (week 0) to week 32</time_frame>
    <description>percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>From baseline (week 0) to week 32</time_frame>
    <description>Kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>From baseline (week 0) to week 37</time_frame>
    <description>Count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of clinically significant hypoglycaemic episodes (level 2) (below 3.0mmol/L (54mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3)</measure>
    <time_frame>From baseline (week 0) to week 37</time_frame>
    <description>Count of episodes</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Cagrilintide 2.4 mg and semaglutide 2.4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive cagrilintide and semaglutide once a week as injections for 32 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cagrilintide 2.4 mg and placebo (semaglutide)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive cagrilintide and placebo (semaglutide) once a week as injections for 32 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Semaglutide 2.4 mg and Placebo (cagrilintide)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive semaglutide and placebo (cagrilintide) once a week as injections for 32 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide 2.4 mg</intervention_name>
    <description>Semaglutide administered s.c. (subcutaneously, under the skin) once weekly. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks</description>
    <arm_group_label>Cagrilintide 2.4 mg and semaglutide 2.4 mg</arm_group_label>
    <arm_group_label>Semaglutide 2.4 mg and Placebo (cagrilintide)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cagrilintide 2.4 mg</intervention_name>
    <description>Cagrilintide administered s.c. (subcutaneously, under the skin) once weekly. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks</description>
    <arm_group_label>Cagrilintide 2.4 mg and placebo (semaglutide)</arm_group_label>
    <arm_group_label>Cagrilintide 2.4 mg and semaglutide 2.4 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (semaglutide)</intervention_name>
    <description>Placebo (semaglutide) administered s.c. (subcutaneously, under the skin) once weekly.&#xD;
Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks</description>
    <arm_group_label>Cagrilintide 2.4 mg and placebo (semaglutide)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (cagrilintide)</intervention_name>
    <description>Placebo (cagrilintide) administered s.c. (subcutaneously, under the skin) once weekly.&#xD;
Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks</description>
    <arm_group_label>Semaglutide 2.4 mg and Placebo (cagrilintide)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female of non-childbearing potential or male&#xD;
&#xD;
          -  Age above or equal to 18 years at the time of signing informed consent&#xD;
&#xD;
          -  Body mass index (BMI) greater than or equal to 27.0 kg/m^2&#xD;
&#xD;
          -  Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days before&#xD;
             screening&#xD;
&#xD;
          -  Glycated haemoglobin (HbA1c) of 7.5-10.0% (58-86 mmol/mol) (both inclusive) as&#xD;
             assessed by central laboratory at screening&#xD;
&#xD;
          -  Stable daily dose(s) â‰¥ 90 days before screening of the following antidiabetic drug(s)&#xD;
             or combination regimen(s) at maximum tolerated or effective dose as judged by the&#xD;
             investigator: metformin with or without Sodium-glucose co-transporter-2 (SGLT2)&#xD;
             inhibitor&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with any medication for the indication of diabetes or obesity other than&#xD;
             stated in the inclusion criteria within 90 days before screening. However, short term&#xD;
             insulin treatment for a maximum of 14 days and prior insulin treatment for gestational&#xD;
             diabetes are allowed&#xD;
&#xD;
          -  Renal impairment with estimated Glomerular Filtration Rate (eGFR) below 60&#xD;
             ml/min/1.73m^2 by central laboratory at screening&#xD;
&#xD;
          -  Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by&#xD;
             a fundus examination performed within 90 days before screening or in the period&#xD;
             between screening and randomisation. Pharmacological pupil-dilation is a requirement&#xD;
             unless using a digital fundus photography camera specified for non-dilated examination&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Transparency (dept. 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <phone>(+1) 866-867-7178</phone>
    <email>clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <zip>91978</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32825</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Gillespie</city>
        <state>Illinois</state>
        <zip>62033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Oxon Hill</city>
        <state>Maryland</state>
        <zip>20745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77079</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Olympia</city>
        <state>Washington</state>
        <zip>98502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 16, 2021</study_first_submitted>
  <study_first_submitted_qc>July 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

